Provided by Tiger Trade Technology Pte. Ltd.

DUALITYBIO-B

170.300
-13.600-7.40%
Volume:1.38M
Turnover:240.08M
Market Cap:15.47B
PE:-3.66
High:182.200
Open:181.500
Low:170.000
Close:183.900
52wk High:563.500
52wk Low:158.500
Shares:90.83M
HK Float Shares:90.83M
Volume Ratio:1.53
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-46.479
ROE:-65.93%
ROA:-24.28%
PB:9.13
PE(LYR):-3.66
PS:15.73

Loading ...

DUALITYBIO-B Inks Landmark Global ADC Collaboration with Roche's Genentech Using Proprietary DUPAC Platform

Stock News
·
Aug 28

DualityBio Signs US$45.00 Million Upfront Collaboration With Genentech to Advance DUPAC-Based Next-Generation ADCs

Bulletin Express
·
Aug 28

Duality Biotherapeutics Inc - Global Research and Development Collaboration and License Agreement with Genentech

THOMSON REUTERS
·
Aug 28

Duality Biotherapeutics - Genentech to Obtain Exclusive Worldwide License to Collaboration Antibody-Drug Conjugates

THOMSON REUTERS
·
Aug 28

Duality Biotherapeutics - Dualitybio-B to Receive Upfront Payment of US$45 Mln Under Collaboration Agreement

THOMSON REUTERS
·
Aug 28

Duality Biotherapeutics Signs Genentech Pact for Next-Generation ADCs, Gets US$45 Million Upfront

Reuters
·
Aug 28

HK Movers | Biotech Stocks Jump. CANSINOBIO Surges 17%; Innovent Bio up 11%; Akeso up over 8%; Everest Med up 7%

Tiger Newspress
·
Aug 26

Movement Alert|DUALITYBIO-B Rises 5.12% in Regular Trading, Innovative Drug Sector Rally and Interim Results Approaching

Market Focus
·
Aug 25

Earning Preview: DUALITYBIO-B revenue outlook undisclosed and institutions tilt bullish

Earnings Agent
·
Aug 21

Movement Alert|DUALITYBIO-B Rises 5.22% in Regular Trading, UBS Initiates Coverage with Buy Rating as Interim Results Approach

Market Focus
·
Aug 21

Movement Alert|DUALITYBIO-B Rises 5.56% in Regular Trading, UBS Initiates Coverage with Buy Rating Amid Sector Strength

Market Focus
·
Aug 20

UBS Initiates Coverage on DUALITYBIO-B with "Buy" Rating and HK$320 Target Price

Deep News
·
Aug 17

Movement Alert|DUALITYBIO-B Falls 5.14% in Regular Trading, Biotech Sector Under Pressure Amid BioNTech Partnership Uncertainty

Market Focus
·
Aug 17

Everest Medicines Appoints Yue Wang as Non-Executive Director

Reuters
·
Aug 14

Duality Biotherapeutics Schedules 28 Aug 2026 Board Meeting to Review 1H 2026 Unaudited Results

Bulletin Express
·
Aug 14

Movement Alert|DUALITYBIO-B Rises 5.28% in Regular Trading, Biotech Sector Rally Extends Valuation Recovery

Market Focus
·
Aug 11

Movement Alert|DUALITYBIO-B Rises 5.09% in Regular Trading, Biotech Sector Strength Drives Rebound Continuation

Market Focus
·
Aug 07

DualityBio issues 0.28 million new shares in July; public float remains compliant

Bulletin Express
·
Aug 05

Movement Alert|DUALITYBIO-B Rises 5.15% in Regular Trading, Innovative Drug Sector Sentiment Recovery and Breakthrough Therapy Designation Boost Shares

Market Focus
·
Aug 04

Movement Alert|DUALITYBIO-B Falls 5.23% in Regular Trading, GSK Competitive Pressure and Lock-up Expiry Concerns Persist

Market Focus
·
Aug 03